Home | Publications | Animal / Veterinary place holder
place holder place holder

Animal / Veterinary

Animal Pharm's Top 20

2006 edition

Publication Date   January 2006
Publisher   Animal Pharm
Product Type   Report
Pages   283
ISBN Number   not applicable
Product Code   ANP024
Ask a question about this product?

Price £795.00

approximately: $1,185 | €947

Summary


This report profiles the businesses of 20 leading companies that generate aggregate annual revenues equivalent in value to more than three-quarters of global animal health and nutrition product sales. Each profile analyses the background of the company concerned, and examines in detail the size, structure and recent performance of its animal health business. Information on individual company strategies, R&D pipelines and future performance prospects is also provided.
Information sources used to compile the report include the Informa newsletter, Animal Pharm World Animal Health and Nutrition News; a range of other trade press sources; corporate web sites, annual reports, presentations and other publications; and contacts within the industry or at individual companies.

The structure of the world animal health and nutrition products market is discussed in an introductory section, which includes tabulated company sales rankings for 2005 and ranking forecasts for 2006. It also includes an analysis of profit levels being generated by leading companies in the sector. Data included in the latter section indicates that pre-tax margins towards the top end of the industry currently average a little over 18%. Among the companies that publish earnings data for their animal health businesses, Eli Lilly's Elanco subsidiary is the most profitable, posting an operating margin of just under 25% in 2005.
Aggregate sales generated by the 20 market leaders rose by a little over 7%.

to almost US$16.3 billion in 2005. Early indications are that a similar increase will be posted in 2006, but individual performances will again vary widely. Perhaps most significantly, Merial appears to be on track to displace Pfizer at the head of the industry sales league during 2006, having booked a sales gain of more than 16% in the first half of the year. Merial is one of six companies expected to report a double-digit increase in revenues this year.

Two of the industry's three biggest businesses - Pfizer and Intervet - will post low single-figure gains, however, and aggregate sales of the 20 market leaders are forecast to rise by a little over 7% once again.

Content


  • CHAPTER 1 INTRODUCTION
    • 1.1 The world market for animal health and nutrition products
      • 1.1.1 Market shares by region
      • 1.1.2 Market shares by product category
      • 1.1.3 Market shares by species
    • 1.2 The animal health and nutrition products industry
      • 1.2.1 Leading companies in the animal health and nutrition sector
        • 1.2.1.1 Market leaders in 2005
        • 1.2.1.2 Market leaders in 2006
      • 1.2.2 Industry profit levels
    • 1.3 Currencies and exchange rates used in this report
  • CHAPTER 2 ADISSEO
    • 2.1 Company background
    • 2.2 Animal nutrition sales
      • 2.2.1 2004 performance
      • 2.2.2 2005 performance
      • 2.2.3 Interim 2006 performance
    • 2.3 Geography of the business
      • 2.3.1 Europe, Middle East, Africa and CIS
      • 2.3.2 Asia/Pacific
      • 2.3.3 Latin America
      • 2.3.4 North America
    • 2.4 Product portfolio
      • 2.4.1 Methionine
      • 2.4.2 Vitamins
      • 2.4.3 Enzymes
    • 2.5 R&D
    • 2.6 Strategy
    • 2.7 Prospects
  • CHAPTER 3 ALPHARMA
    • 3.1 Company background
    • 3.2 Animal health sales and operating profit
      • 3.2.1 2004 performance
      • 3.2.2 2005 performance
      • 3.2.3 Interim 2006 performance
    • 3.3 Geography of the business
      • 3.3.1 US
      • 3.3.2 International markets
    • 3.4 Product portfolio
      • 3.4.1 Antibiotics
      • 3.4.2 Anticoccidials
      • 3.4.3 Antibacterials
      • 3.4.4 Other products
    • 3.5 R&D
    • 3.6 Strategy
    • 3.7 Prospects
  • CHAPTER 4 BASF
    • 4.1 Company background
    • 4.2 Animal nutrition sales
      • 4.2.1 2004 performance
      • 4.2.2 2005 performance
      • 4.2.3 Interim 2006 performance
    • 4.3 Geography of the business
      • 4.3.1 Europe
      • 4.3.2 Americas
      • 4.3.3 Asia/Pacific
    • 4.4 Product portfolio
      • 4.4.1 Vitamins
      • 4.4.2 Aminacids
      • 4.4.3 Carotenoids
      • 4.4.4 Enzymes
      • 4.4.5 Other products
    • 4.5 R&D
    • 4.6 Strategy
    • 4.7 Prospects
  • CHAPTER 5 BAYER
    • 5.1 Company background
    • 5.2 Animal health sales and operating income
      • 5.2.1 2004 performance
      • 5.2.2 2005 performance
      • 5.2.3 Interim 2006 performance
    • 5.3 Geography of the business
      • 5.3.1 North America
      • 5.3.2 Europe
      • 5.3.3 Asia/Pacific
      • 5.3.4 Latin America, Africa & Middle East
    • 5.4 Product portfolio
      • 5.4.1 Antiparasitics
      • 5.4.2 Antimicrobials
      • 5.4.3 Other products
    • 5.5 R&D
    • 5.6 Strategy
    • 5.7 Prospects
  • CHAPTER 6 BOEHRINGER INGELHEIM
    • 6.1 Company background
    • 6.2 Animal health sales
      • 6.2.1 2004 performance
      • 6.2.2 2005 performance
      • 6.2.3 Interim 2006 performance
    • 6.3 Geography of the business
      • 6.3.1 Europe
      • 6.3.2 North America
      • 6.3.3 Other markets
    • 6.4 Product portfolio
      • 6.4.1 Pharmaceuticals
      • 6.4.2 Biologicals
      • 6.4.3 Other products
    • 6.5 R&D
    • 6.6 Strategy
    • 6.7 Prospects
  • CHAPTER 7 CEVA
    • 7.1 Company background
    • 7.2 Animal health sales and earnings
      • 7.2.1 2004 performance
      • 7.2.2 2005 performance
      • 7.2.3 Interim 2006 performance
    • 7.3 Geography of the business
      • 7.3.1 Europe
      • 7.3.2 International markets
    • 7.4 Product portfolio
      • 7.4.1 Companion animal and behavioral products
      • 7.4.2 Reproductive controls
      • 7.4.3 Anti-infectives
      • 7.4.4 Vaccines
      • 7.4.5 Others
    • 7.5 R&D
    • 7.6 Strategy
    • 7.7 Prospects
  • CHAPTER 8 DAINIPPON SUMITOMO PHARMA
    • 8.1 Company background
    • 8.2 Animal health sales and operating profit
      • 8.2.1 Fiscal 2005 performance
      • 8.2.2 Fiscal 2006 performance
    • 8.3 Geography of the business
    • 8.4 Product portfolio
      • 8.4.1 Companion animal products
      • 8.4.2 Food animal products
    • 8.5 R&D
    • 8.6 Strategy
    • 8.7 Prospects
  • CHAPTER 9 DEGUSSA
    • 9.1 Company background
    • 9.2 Feed additive sales
      • 9.2.1 2004 performance
      • 9.2.2 2005 performance
      • 9.2.3 Interim 2006 performance
    • 9.3 Geography of the business
    • 9.4 Product portfolio
      • 9.4.1 Methionine
      • 9.4.2 Other aminacids
    • 9.5 R&D
    • 9.6 Strategy
    • 9.7 Prospects
  • CHAPTER 10 DSM
    • 10.1 Company background
    • 10.2 Animal nutrition sales
      • 10.2.1 2004 performance
      • 10.2.2 2005 performance
      • 10.2.3 Interim 2006 performance
    • 10.3 Geography of the business
    • 10.4 Product portfolio
      • 10.4.1 Vitamins
      • 10.4.2 Carotenoids
      • 10.4.3 Feed enzymes
      • 10.4.4 Other products
    • 10.5 R&D
    • 10.6 Strategy
    • 10.7 Prospects
  • CHAPTER 11 ELANCO
    • 11.1 Company background
    • 11.2 Animal health sales and operating income
      • 11.2.1 2004 performance
      • 11.2.2 2005 performance
      • 11.2.3 Interim 2006 performance
    • 11.3 Geography of the business
      • 11.3.1 US
      • 11.3.2 International markets
    • 11.4 Product portfolio
      • 11.4.1 Tylosin
      • 11.4.2 Tilmicosin
      • 11.4.3 Monensin
      • 11.4.4 Avilamycin
      • 11.4.5 Ractopamine
      • 11.4.6 Other products
    • 11.5 R&D
    • 11.6 Strategy
    • 11.7 Prospects
  • CHAPTER 12 FORT DODGE
    • 12.1 Company background
    • 12.2 Animal health sales and operating profit
      • 12.2.1 2004 performance
      • 12.2.2 2005 performance
      • 12.2.3 Interim 2006 performance
    • 12.3 Geography of the business
      • 12.3.1 US
      • 12.3.2 International markets
    • 12.4 Product portfolio
      • 12.4.1 Biologicals
      • 12.4.2 Antiparasitics
      • 12.4.3 Other pharmaceuticals
    • 12.5 R&D
    • 12.6 Strategy
    • 12.7 Prospects
  • CHAPTER 13 IDEXX
    • 13.1 Company background
    • 13.2 Sales and income
      • 13.2.1 2004 performance
      • 13.2.2 2005 performance
      • 13.2.3 Interim 2006 performance
    • 13.3 Geography of the business
      • 13.3.1 North America
      • 13.3.2 International markets
    • 13.4 Product portfolio
      • 13.4.1 Companion animal group
        • 13.4.1.1 Immunoassays
        • 13.4.1.2 Veterinary instrument systems
        • 13.4.1.3 Reference laboratory and consulting services
        • 13.4.1.4 Information management and radiography
        • 13.4.1.5 Veterinary pharmaceuticals
      • 13.4.2 Water products and services
      • 13.4.3 Food diagnostics group
    • 13.5 R&D
    • 13.6 Strategy
    • 13.7 Prospects
  • CHAPTER 14 INTERVET
    • 14.1 Company background
    • 14.2 Animal health sales and operating profit
      • 14.2.1 2004 performance
      • 14.2.2 2005 performance
      • 14.2.3 Interim 2006 performance
    • 14.3 Geography of the business
      • 14.3.1 Europe
      • 14.3.2 Americas
      • 14.3.3 Other markets
    • 14.4 Product portfolio
      • 14.4.1 Biologicals
      • 14.4.2 Antiparasitics
      • 14.4.3 Anti-infectives
      • 14.4.4 Other products
    • 14.5 R&D
    • 14.6 Strategy
    • 14.7 Prospects
  • CHAPTER 15 MERIAL
    • 15.1 Company background
    • 15.2 Animal health sales
      • 15.2.1 2004 performance
      • 15.2.2 2005 performance
      • 15.2.3 Interim 2006 performance
    • 15.3 Geography of the business
      • 15.3.1 US
      • 15.3.2 Europe
      • 15.3.3 International
    • 15.4 Product portfolio
      • 15.4.1 Avermectins
      • 15.4.2 Fipronil
      • 15.4.3 Biologicals
      • 15.4.4 Other products
    • 15.5 R&D
    • 15.6 Strategy
    • 15.7 Prospects
  • CHAPTER 16 NOVARTIS
    • 16.1 Company background
    • 16.2 Animal health sales and operating profit
      • 16.2.1 2004 performance
      • 16.2.2 2005 performance
      • 16.2.3 Interim 2006 performance
    • 16.3 Geography of the business
      • 16.3.1 North America
      • 16.3.2 Europe
      • 16.3.3 Other markets
    • 16.4 Product portfolio
      • 16.4.1 Antiparasitics
      • 16.4.2 Anti-infectives
      • 16.4.3 Other pharmaceuticals
      • 16.4.4 Vaccines
    • 16.5 R&D
    • 16.6 Strategy
    • 16.7 Prospects
  • CHAPTER 17 PFIZER
    • 17.1 Company background
    • 17.2 Animal health sales and operating profit
      • 17.2.1 2004 performance
      • 17.2.2 2005 performance
      • 17.2.3 Interim 2006 performance
    • 17.3 Geography of the business
      • 17.3.1 US
      • 17.3.2 International markets
    • 17.4 Product portfolio
      • 17.4.1 Anti-infectives
      • 17.4.2 Antiparasitics
      • 17.4.3 Vaccines
      • 17.4.4 Other pharmaceuticals
    • 17.5 R&D
    • 17.6 Strategy
    • 17.7 Prospects
  • CHAPTER 18 PHIBRO
    • 18.1 Company background
    • 18.2 Animal health & nutrition sales and operating profit
      • 18.2.1 Fiscal 2004 performance
      • 18.2.2 Fiscal 2005 performance
      • 18.2.3 Interim fiscal 2006 performance
    • 18.3 Geography of the business
    • 18.4 Product portfolio
      • 18.4.1 PhibrAnimal Health
      • 18.4.2 Koffolk
      • 18.4.3 Prince Agri Products
    • 18.5 R&D
    • 18.6 Strategy
    • 18.7 Prospects
  • CHAPTER 19 SCHERING-PLOUGH
    • 19.1 Company background
    • 19.2 Animal health sales and earnings
      • 19.2.1 2004 performance
      • 19.2.2 2005 performance
      • 19.2.3 Interim 2006 performance
    • 19.3 Geography of the business
      • 19.3.1 US
      • 19.3.2 International markets
    • 19.4 Product portfolio
      • 19.4.1 Antiparasitics
      • 19.4.2 Anti-infectives
      • 19.4.3 Vaccines
      • 19.4.4 Other products
    • 19.5 R&D
    • 19.6 Strategy
    • 19.7 Prospects
  • CHAPTER 20 VETOQUINOL
    • 20.1 Company background
    • 20.2 Animal health sales
      • 20.2.1 2004 performance
      • 20.2.2 2005 performance
      • 20.2.3 Interim 2006 performance
    • 20.3 Geography of the business
      • 20.3.1 Europe
      • 20.3.2 North America
      • 20.3.3 Other markets
    • 20.4 Product portfolio
      • 20.4.1 Anti-infectives
      • 20.4.2 Other pharmaceuticals
      • 20.4.3 Other products
    • 20.5 R&D
    • 20.6 Strategy
    • 20.7 Prospects
  • CHAPTER 21 VIRBAC
    • 21.1 Company background
    • 21.2 Animal health sales and operating profit
      • 21.2.1 2004 performance
      • 21.2.2 2005 performance
      • 21.2.3 Interim 2006 performance
    • 21.3 Geography of the business
      • 21.3.1 Europe
      • 21.3.2 North America
      • 21.3.3 Other markets
    • 21.4 Product portfolio
      • 21.4.1 Antiparasitics
      • 21.4.2 Anti-infectives
      • 21.4.3 Biologicals
      • 21.4.4 Other products
    • 21.5 R&D
    • 21.6 Strategy
    • 21.7 Prospects
  • LIST OF TABLES
    • Table 1.1 Geography of the world market, 2005
    • Table 1.2 World market structure by product category, 2005
    • Table 1.3 World market structure by species, 2005
    • Table 1.4 Top 20 rankings, 2005
    • Table 1.5 Top 20 ranking forecasts, 2006
    • Table 1.6 Leading animal health company earnings in 2005
    • Table 2.1 Adisseanimal nutrition sales, 2001-2005
    • Table 2.2 Adissesales by region, 2005
    • Table 3.1 Alpharma's revenues by division, 2005
    • Table 3.2 Alpharma animal health sales, 2001-2005
    • Table 3.3 Alpharma animal health earnings and margins, 2001-2005
    • Table 3.4 Alpharma first half sales, 2005 and 2006
    • Table 3.5 Alpharma's major product sales, 2005
    • Table 4.1 BASF sales by operating segment, 2005
    • Table 4.2 BASF animal nutrition sales, 2001-2005
    • Table 5.1 Bayer sales by operating segment, 2005
    • Table 5.2 Bayer animal health sales, 2001-2005
    • Table 5.3 Bayer animal health earnings and margins, 2001-2005
    • Table 5.4 Bayer's first half sales, 2005-2006
    • Table 5.5 Bayer animal health sales by region, 2005
    • Table 5.6 Bayer animal health sales by species segment, 2004 and 2005
    • Table 5.7 Bayer's imidacloprid sales, 2001-2005
    • Table 5.8 Bayer animal health research spending, 2001-2005
    • Table 5.9 Bayer's late-stage development pipeline
    • Table 6.1 Boehringer Ingelheim sales by business area, 2005
    • Table 6.2 BIV sales, 2001-2004
    • Table 6.3 BIV sales by region, 2005
    • Table 6.4 Sales of key BIV pharmaceutical brands
    • Table 6.5 BIV spending on R&D, 2001-2005
    • Table 7.1 Ceva animal health sales, 2001-2005
    • Table 7.2 Ceva earnings and operating margins, 2001-2005
    • Table 7.3 Ceva's first half sales, 2005 and 2006
    • Table 7.4 Ceva animal health sales by region, 2005
    • Table 7.5 Ceva animal health sales by species, 2005
    • Table 8.1 DSP sales by business segment, fiscal 2006
    • Table 8.2 DSP Animal Science sales, fiscal 2002-2006
    • Table 8.3 DSP Animal Science sales by product sector, fiscal 2006
    • Table 9.1 Degussa sales by operating segment, 2005
    • Table 9.2 Degussa feed additive sales, 2001-2005
    • Table 10.1 DSM sales by operating segment, 2005
    • Table 11.1 Elanco's animal health sales, 2001-2005
    • Table 11.2 Elanco's operating income and margin, 2001-2005
    • Table 11.3 Elanco's interim 2006 sales performance
    • Table 11.4 Elanco's US/international sales split, 2001-2005
  • List of Tables Animal Pharm's Top 20: 2006 Edition
    • Table 12.1 Wyeth sales by operating segment, 2005
    • Table 12.2 Fort Dodge animal health sales, 2001-2005
    • Table 12.3 Fort Dodge operating income and margins, 2001-2005
    • Table 12.4 Fort Dodge first half sales, 2005-2006
    • Table 12.5 Fort Dodge US/international sales split, 2001-2005
    • Table 12.6 Fort Dodge sales by species, 2005
    • Table 13.1 Idexx sales, 2001-2005
    • Table 13.2 Idexx earnings and operating margin, 2001-2005
    • Table 13.3 Idexx first half sales, 2005 and 2006
    • Table 13.4 Idexx sales by region, 2005
    • Table 13.5 Idexx sales by operating segment, 2005
    • Table 13.6 Companion animal group revenues by business area
    • Table 13.7 Idexx spending on R&D, 2001-2005
    • Table 14.1 AkzNobel sales by operating segment, 2005
    • Table 14.2 Intervet animal health sales, 2001-2005
    • Table 14.3 Intervet's first half sales, 2005 and 2006
    • Table 14.4 Intervet sales by region, 2005
    • Table 14.5 Intervet sales by product segment, 2005
    • Table 15.1 Merial animal health sales, 2001-2005
    • Table 15.2 Merial first half animal health sales, 2005 and 2006
    • Table 15.3 Merial sales by product category, 2005
    • Table 15.4 Merial's avermectin revenues, 2001-2005
    • Table 15.5 Leading formulations in the Merial ivermectin range
    • Table 15.6 Fipronil sales, 2001-2005
    • Table 16.1 Novartis sales by operating segment, 2005
    • Table 16.2 Novartis animal health sales, 2001-2005
    • Table 16.3 Novartis animal health sales by region, 2005
    • Table 16.4 Novartis animal health sales by product segment, 2005
    • Table 17.1 Pfizer sales by operating segment, 2005
    • Table 17.2 Pfizer animal health sales, 2001-2005
    • Table 17.3 Pfizer animal health operating profit and margins, 2001-2005
    • Table 17.4 Pfizer first half animal health sales, 2005 and 2006
    • Table 17.5 Pfizer's US/international sales split, 2004 and 2005
    • Table 17.6 Pfizer animal health sales by species segment, 2004 and 2005
    • Table 17.7 Recent additions tthe Pfizer anti-infectives range
    • Table 18.1 PAHC sales by operating segment, fiscal 2005
    • Table 18.2 PAHC animal health and nutrition sales, fiscal 2001-2005
    • Table 18.3 PAHC interim animal health sales, fiscal 2006
    • Table 18.4 PAHC animal health and nutrition sales by product category,
      • fiscal 2005
    • Table 19.1 Schering-Plough sales by business sector, 2005
    • Table 19.2 SPAH sales, 2001-2005
    • Table 19.3 SPAH earnings and divisional margins, 2001-2005
    • Table 19.4 SPAH first half sales, 2005 and 2006
    • Table 19.5 SPAH's US/international sales split, 2004 and 2005
    • Table 20.1 Vtoquinol sales, 2001-2005
    • Table 20.2 Vtoquinol sales by region, 2005
    • Table 20.3 Vtoquinol's key acquisitions
  • List of Tables Animal Pharm's Top 20: 2006 Edition
    • Table 20.4 Vtoquinol sales by product category, 2005
    • Table 21.1 Virbac animal health sales, 2001-2005
    • Table 21.2 Virbac first half sales, 2005 and 2006
    • Table 21.3 Virbac sales by region, 2005
    • Table 21.4 Virbac sales by product segment, 2005